Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013

Executive Summary

Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.

Advertisement

Related Content

Schizophrenia Dominates Psychiatric Drug Deal-Making Since 2008
When Opportunity Knocks: Eisai Turns To Business Development
Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation
Beyond Bapi: Alzheimer’s Pipeline Runs Deep
AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction
First Deal Of Scangos Era Brings Phase II ALS Candidate To Biogen Idec

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel